Erbitux Review Required Six Months Because BLA Was Not Rolling, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency notes speedier reviews are generally a function of an application’s rolling status because the user fee clock does not start until the filing of the application is complete.